At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
AZD3199 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a β2-agonist) Compared to Formoterol in Asthmatic Patients
In Brief
A Phase 2 clinical trial evaluating AZD3199, Formoterol, and 1 other intervention for Asthma and Airway Obstruction. Completed, enrolled 37 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Airway Obstruction
CountriesDenmark, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedAug 18, 2008
Enrollment StartAug 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.9 years ago
Interventions
AZD3199drug
Dry powder for inhalation, single dose
Formoteroldrug
Dry powder for inhalation, single dose
Placebodrug
Dry powder for inhalation, single dose